Asset Management One Co. holds $8.01 million in Bio-Techne Corp. stocks. There have been concerns about the corporation's underperformance in the Nasdaq, though it bested competitors on a strong trading day. Bio-Techne announced partnerships with USP and Leica Biosystems, promising quicker development of monoclonal antibody and gene therapy products. Announcements spotlight Bio-Techne's strong Q3 2025 earnings, with impressive organic growth amid a global environment. Despite some challenges with funding from NIH, Bio-Techne showed a solid footing in light of macroeconomic uncertainty. They announced initiatives at multiple investor conferences, and launched a $500 million Share Repurchase Program. Their new high-throughput Simple Western System Leo has begun shipping, and recent appointees and partnerships promise substantial expansion and innovation. Some concerns have risen about whether Bio-Techne is assuming excessive debt.
Bio-Techne Corp TECH News Analytics from Mon, 29 Jul 2024 07:00:00 GMT to Sat, 28 Jun 2025 07:58:14 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor -2
